MX2016010954A - Construcciones de proteina superficial ubicua a2 y usos de las mismas. - Google Patents

Construcciones de proteina superficial ubicua a2 y usos de las mismas.

Info

Publication number
MX2016010954A
MX2016010954A MX2016010954A MX2016010954A MX2016010954A MX 2016010954 A MX2016010954 A MX 2016010954A MX 2016010954 A MX2016010954 A MX 2016010954A MX 2016010954 A MX2016010954 A MX 2016010954A MX 2016010954 A MX2016010954 A MX 2016010954A
Authority
MX
Mexico
Prior art keywords
uspa2
compositions
immunogenic compositions
protein constructs
constructs
Prior art date
Application number
MX2016010954A
Other languages
English (en)
Other versions
MX376079B (es
Inventor
Normand Blais
Castado Cindy
Chomez Patrick
Dewerchin Marianne
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2016010954A publication Critical patent/MX2016010954A/es
Publication of MX376079B publication Critical patent/MX376079B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/104Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045Moraxella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Gram-negative bacteria
    • C07K16/1217Neisseriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Gram-negative bacteria
    • C07K16/1218Acinetobacter (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden la proteína superficial ubicua A2 (UspA2) de Moraxella catarrhalis (M. catarrhalis); de una manera más particular, la presente solicitud se refiere a construcciones de proteína UspA2 y a composiciones inmunogénicas que comprenden las construcciones, a vacunas que comprenden estas composiciones inmunogénicas, y a los usos terapéuticos de las mismas; la invención se refiere además a composiciones que comprenden UspA2 en combinación con cuando menos un antígeno a partir de Haemophilus influenzae, a composiciones inmunogénicas que comprenden los antígenos, a vacunas que comprenden estas composiciones inmunogénicas, y a los usos terapéuticos de las mismas.
MX2016010954A 2014-02-24 2015-02-20 Construcciones de proteina superficial ubicua a2 y usos de las mismas. MX376079B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461943909P 2014-02-24 2014-02-24
US201461946932P 2014-03-03 2014-03-03
US201461946937P 2014-03-03 2014-03-03
PCT/IB2015/051308 WO2015125118A1 (en) 2014-02-24 2015-02-20 Uspa2 protein constructs and uses thereof

Publications (2)

Publication Number Publication Date
MX2016010954A true MX2016010954A (es) 2016-11-11
MX376079B MX376079B (es) 2025-03-07

Family

ID=52629643

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010954A MX376079B (es) 2014-02-24 2015-02-20 Construcciones de proteina superficial ubicua a2 y usos de las mismas.

Country Status (28)

Country Link
US (3) US10040832B2 (es)
EP (2) EP3110438B1 (es)
JP (1) JP6585085B2 (es)
KR (1) KR102515835B1 (es)
CN (2) CN111499701A (es)
AU (1) AU2015220369B2 (es)
BE (1) BE1022345A9 (es)
BR (1) BR112016019525B1 (es)
CA (1) CA2939862C (es)
CY (2) CY1121535T1 (es)
DK (2) DK3110438T3 (es)
EA (1) EA034352B1 (es)
ES (2) ES2899300T3 (es)
HR (2) HRP20211926T1 (es)
HU (2) HUE057505T2 (es)
IL (1) IL246994B (es)
LT (2) LT3110438T (es)
ME (1) ME03335B (es)
MX (1) MX376079B (es)
PL (2) PL3498292T3 (es)
PT (2) PT3110438T (es)
RS (2) RS58451B1 (es)
SG (1) SG11201606272PA (es)
SI (2) SI3110438T1 (es)
SM (2) SMT201900166T1 (es)
TW (1) TW201620927A (es)
UY (1) UY36006A (es)
WO (1) WO2015125118A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Uspa2蛋白質構築體及其用途
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CA3057778A1 (en) * 2017-03-31 2018-10-04 Glaxosmithkline Biologicals Sa Immunogenic composition, use and method of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
FR3066920A1 (fr) 2017-05-30 2018-12-07 Glaxosmithkline Biologicals S.A. Nouveaux procedes de fabrication d'un adjuvant
CA3072018A1 (en) 2017-08-14 2019-02-21 Glaxosmithkline Biologicals Sa Methods of boosting immune responses
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
GB201803692D0 (en) * 2018-03-08 2018-04-25 Glaxosmithkline Biologicals Sa Immunogenic composition
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
CN112912097A (zh) * 2018-08-23 2021-06-04 葛兰素史密丝克莱恩生物有限公司 免疫原性蛋白和组合物
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
JP2022543264A (ja) * 2019-08-05 2022-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロテインdポリペプチドを含む組成物を調製するプロセス
EP4010014A1 (en) 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US20230266317A1 (en) 2019-09-11 2023-08-24 Glaxosmithkline Biologicals Sa Antigen binding protein and assays
EP4294433A1 (en) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Immunogenic composition, use and methods
EP4558170A1 (en) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Continuous process for vaccine production

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
ATE497004T1 (de) * 1996-12-20 2011-02-15 Univ Texas Moraxella catarrhalis antigene uspa1 und uspa2
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
WO2002083710A2 (en) * 2001-04-13 2002-10-24 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
AU2002355197A1 (en) * 2001-07-27 2003-02-17 Chiron Srl Meningococcus adhesins nada, app and orf 40
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
UA95456C2 (ru) * 2005-08-10 2011-08-10 Арне Форсгрен Аб Взаимодействие moraxella catarrhalis с эпителиальными клетками, внеклеточными матриксными белками и системой комплемента
US8092811B2 (en) * 2005-08-10 2012-01-10 Arne Forsgren Ab Interaction of Moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
SG10201600336RA (en) * 2006-01-17 2016-02-26 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein e; pe)
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
JP2014516028A (ja) * 2011-05-11 2014-07-07 リースベック ヘルスケア スウェーデン アクティエボラーグ ラミニン及びビトロネクチン結合特性を有するタンパク質f−新規インフルエンザ菌付着因子
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Uspa2蛋白質構築體及其用途

Also Published As

Publication number Publication date
IL246994B (en) 2020-11-30
EP3498292A1 (en) 2019-06-19
SI3498292T1 (sl) 2022-01-31
HUE057505T2 (hu) 2022-05-28
ES2899300T3 (es) 2022-03-10
ME03335B (me) 2019-10-20
EP3110438A1 (en) 2017-01-04
CN106061995A (zh) 2016-10-26
IL246994A0 (en) 2016-09-29
UY36006A (es) 2015-09-30
CA2939862C (en) 2022-12-06
KR20160124774A (ko) 2016-10-28
RS62592B1 (sr) 2021-12-31
JP2017507181A (ja) 2017-03-16
US20200325184A1 (en) 2020-10-15
CA2939862A1 (en) 2015-08-27
PL3110438T3 (pl) 2019-06-28
AU2015220369A1 (en) 2016-09-15
BE1022345B1 (fr) 2016-03-25
BR112016019525B1 (pt) 2024-01-02
SI3110438T1 (sl) 2019-05-31
PL3498292T3 (pl) 2022-02-14
US10947280B2 (en) 2021-03-16
JP6585085B2 (ja) 2019-10-02
US20170008932A1 (en) 2017-01-12
HRP20190412T1 (hr) 2019-04-19
BE1022345A9 (fr) 2016-11-16
US10745449B2 (en) 2020-08-18
SMT201900166T1 (it) 2019-05-10
KR102515835B1 (ko) 2023-03-31
MX376079B (es) 2025-03-07
EA034352B1 (ru) 2020-01-30
DK3110438T3 (en) 2019-03-25
BR112016019525A2 (pt) 2017-10-24
SMT202100728T1 (it) 2022-01-10
US10040832B2 (en) 2018-08-07
CY1121535T1 (el) 2020-05-29
DK3498292T3 (da) 2022-01-03
TW201620927A (zh) 2016-06-16
SG11201606272PA (en) 2016-09-29
PT3110438T (pt) 2019-03-29
EP3110438B1 (en) 2019-01-02
EA201691611A1 (ru) 2016-12-30
WO2015125118A1 (en) 2015-08-27
AU2015220369B2 (en) 2018-02-01
RS58451B1 (sr) 2019-04-30
ES2715674T3 (es) 2019-06-05
HUE042054T2 (hu) 2019-06-28
PT3498292T (pt) 2021-11-18
HRP20211926T1 (hr) 2022-03-18
LT3110438T (lt) 2019-04-10
US20180354996A1 (en) 2018-12-13
CY1124979T1 (el) 2022-11-25
LT3498292T (lt) 2021-11-25
EP3498292B1 (en) 2021-10-20
CN111499701A (zh) 2020-08-07

Similar Documents

Publication Publication Date Title
MX2016010954A (es) Construcciones de proteina superficial ubicua a2 y usos de las mismas.
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
MX387985B (es) Particulas tipo virus modificadas de cmv.
DOP2013000235A (es) Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae.
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
IL255106A0 (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
EP3012322A4 (en) GENEELED STRAIN VARIANT OF PORCINE PSEUDORABIES VIRUS, VACCINE COMPOSITION, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
EA201691348A1 (ru) Однофлаконные вакцинные составы
EA201790294A1 (ru) Средства на основе флагеллина и применения, включающие эффективную вакцинацию
MX2015010783A (es) Composicion de vacuna.
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
DK3146042T3 (da) Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma
MX2015013304A (es) Vacunas de nucleoproteina de la influenza.
BR112014020025A8 (pt) Vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
MX2016010838A (es) Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9).
CL2019000705A1 (es) Nuevos promotores.
MX381745B (es) Vacunas de pestivirus para temblores congenitos.
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
EP3538197A4 (en) DEVICES AND METHODS FOR IMPROVING IMMUNOGENICITY TO INTRADERMAL VACCINATION
MX374919B (es) ANTÍGENOS Y COMBINACIONES DE ANTÍGENOS PARA USARSE PARA ELEVAR LA RESPUESTA INMUNE CONTRA Haemophilus influenzae.

Legal Events

Date Code Title Description
FG Grant or registration